AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T18:44:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
Tue 13 May 25, 08:01 PMDaré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
Mon 31 Mar 25, 08:01 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -13.39927M | -4.05360M | -30.16139M | -30.94774M | -38.69611M |
| Minority interest | - | - | - | - | - |
| Net income | -13.39927M | -4.05360M | -30.16139M | 406.80M | -38.32622M |
| Selling general administrative | 8.76M | 8.36M | 11.31M | 11.24M | 8.45M |
| Selling and marketing expenses | - | 0.80M | 0.60M | - | - |
| Gross profit | -1.41699M | -14.29542M | -18.83019M | 10.00M | - |
| Reconciled depreciation | 1.63M | 0.04M | 0.04M | 0.02M | 0.03M |
| Ebit | -13.55233M | -23.45149M | -30.73988M | -31.40969M | -39.06851M |
| Ebitda | -11.40095M | -23.40916M | -30.70152M | -31.38549M | -39.41199M |
| Depreciation and amortization | 2.15M | 0.04M | 0.04M | 0.02M | -0.34347M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -13.55233M | -23.45149M | -30.93988M | -31.38549M | -39.06851M |
| Other operating expenses | 14.58M | 23.46M | 33.75M | 41.39M | 39.07M |
| Interest expense | 0.82M | - | - | -437.75000M | 0.37M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -4049.54540M | -0.00000M | -437.75000M | -0.36989M |
| Total revenue | 1.03M | 0.00978M | 2.81M | 10.00M | 0.00000M |
| Total operating expenses | 12.14M | 9.16M | 12.11M | 41.39M | 39.07M |
| Cost of revenue | 2.45M | 14.31M | 21.64M | - | - |
| Total other income expense net | 0.15M | 19.40M | 0.78M | 0.44M | 0.37M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -13.39927M | -4.05360M | -41.04705M | -30.94774M | -38.69611M |
| Net income applicable to common shares | - | - | - | -30.94774M | -38.69611M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 32.47M | 22.10M | 21.28M | 43.83M | 55.81M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | -24684.86518M | 2.52M | 6.12M | 6.67M | 2476.61M |
| Total liab | 29.63M | 28.11M | 26.33M | 32.71M | 17.05M |
| Total stockholder equity | 2.84M | -6.01209M | -5.04764M | 11.11M | 38.75M |
| Deferred long term liab | - | - | - | - | 0.14M |
| Other current liab | 20.39M | 3.04M | 2.89M | 10.89M | 3.14M |
| Common stock | 0.00145M | 0.00087M | 0.01000M | 0.00848M | 0.00839M |
| Capital stock | 0.00145M | 0.00087M | 0.01000M | 0.00848M | 0.00839M |
| Retained earnings | -188.68890M | -175.28963M | -171.23603M | -141.07464M | -110.12690M |
| Other liab | - | - | - | - | 1.00M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.00000M | - | - | 0.27M |
| Cash | 24711.36M | 15.70M | 10.48M | 34.67M | 51.67M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 23.69M | 21.61M | 20.48M | 31.62M | 16.05M |
| Current deferred revenue | - | 16.56M | 13.74M | 18.30M | 10.54M |
| Net debt | -22055.33700M | -14.39515M | -5.15791M | -34.18087M | -51.40354M |
| Short term debt | 2.10M | 0.55M | 0.47M | 0.40M | 0.27M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 2656.02M | 1.30M | 5.32M | 0.49M | 0.27M |
| Other stockholder equity | 191.95M | 169.71M | 166.54M | 152.53M | 149.03M |
| Property plant equipment | - | - | - | - | 0.24M |
| Total current assets | 27.06M | 18.45M | 17.54M | 43.04M | 55.30M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 26.34M | 38.75M |
| Short term investments | - | 15682.48M | - | - | - |
| Net receivables | 0.57M | 0.23M | 0.95M | 1.70M | 1.15M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | -2474.13539M |
| Accounts payable | 1.20M | 1.46M | 3.39M | 2.03M | 2.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.42162M | -0.42881M | -0.36090M | -0.35131M | -0.15497M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -4396.13432M | 1.11M | 1.43M | 0.26M | 0.27M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5.41M | 3.65M | 3.74M | 0.79M | 0.51M |
| Capital lease obligations | 2.66M | 1.30M | 1.40M | 0.49M | 0.27M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.57305M | -0.02480M | -0.06307M | -0.01452M |
| Change to liabilities | - | - | - | 0.00000M | 10.06M |
| Total cashflows from investing activities | -385.27800M | -0.57305M | -0.62943M | - | -0.01452M |
| Net borrowings | -1.33130M | -0.01756M | 0.27M | - | - |
| Total cash from financing activities | 19277.14M | 0.43M | 15.64M | 1.34M | 75.85M |
| Change to operating activities | - | - | - | - | -0.64733M |
| Net income | -13399.27400M | -4.05360M | -30.16139M | -30.94774M | -38.69611M |
| Change in cash | 9013.18M | 5.19M | -23.85855M | -17.00448M | 47.00M |
| Begin period cash flow | 15998.17M | 10.81M | 34.67M | 51.67M | 4.67M |
| End period cash flow | 25011.36M | 16.00M | 10.81M | 34.67M | 51.67M |
| Total cash from operating activities | -9885.87000M | 5.39M | -38.85665M | -18.08843M | -28.76404M |
| Issuance of capital stock | 20.93M | 0.45M | 8.56M | 1.22M | 75.31M |
| Depreciation | 1634.49M | 0.04M | 0.04M | 0.02M | 0.03M |
| Other cashflows from investing activities | - | -572.47295M | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.34308M | 0.72M | 0.75M | - | -0.68515M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 19256.60M | -0.00219M | 6.02M | 0.12M | 0.53M |
| Change to netincome | - | - | - | - | 1.18M |
| Capital expenditures | 385.28M | 0.57M | 0.63M | 0.06M | 0.01M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.21074M | 5.81M | -10.42689M | 10.70M | 8.73M |
| Stock based compensation | 1496.56M | 2.20M | 2.53M | 2.16M | 1.60M |
| Other non cash items | 382.57M | 1.39M | -0.83742M | -0.02306M | -0.05185M |
| Free cash flow | -10271.14800M | 4.82M | -39.48608M | -18.15150M | -28.77856M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DARE Dare Bioscience Inc |
0.03 1.22% | 2.08 | - | 1.27 | 33.35 | 12.04 | 4.87 | -2.0649 |
| NVO Novo Nordisk A/S |
0.94 2.04% | 46.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
2.93 0.63% | 469.72 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
5.28 0.86% | 617.77 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
3655 Nobel Drive, San Diego, CA, United States, 92122
| Name | Title | Year Born |
|---|---|---|
| Ms. Sabrina Martucci Johnson | Pres, CEO, Sec. & Director | 1967 |
| Ms. Lisa Walters-Hoffert | Chief Financial Officer | 1959 |
| Mr. John A. Fair | Chief Strategy Officer | 1972 |
| Mr. Mark Walters | VP of Operations | 1955 |
| Ms. MarDee J. Haring-Layton | VP of Accounting & Fin. | 1976 |
| Dr. David Friend | Chief Scientific Officer | NA |
| Ms. Sabrina Martucci Johnson | CEO, President, Principal Financial Officer, Secretary & Director | 1967 |
| Ms. Lisa Walters-Hoffert | Executive Officer | 1959 |
| Mr. Mark Walters | Vice President of Operations | 1955 |
| Ms. MarDee J. Haring-Layton | Chief Accounting Officer | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...